Physician profile

Garret Wayne Choby

Otolaryngology · Pittsburgh, PA

NPI 1407141799

$2,137.59

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$503.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $781.71 2022
Stryker Corporation $575.86 2019-2024 Core, Scopis Ent
Acclarent, INC $232.51 2021-2024 Acclarent Balloon Inflation Device, Acclarent Navwire, Acclarent Aera
Integra Lifesciences Corporation $156.05 2024 Acclarent Aera
Intersect Ent, INC. $133.91 2019
Kls-Martin L.P. $94.06 2022
Karl Storz Endoscopy-America $87.65 2019
Medtronic USA, INC. $75.84 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Garret Wayne Choby

$2,137.59

in general payments reported 2019-2025

Years
2019-2024
Top company
Medtronic, INC.

https://glasscript.com/doctor/335523/garret-wayne-choby

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.